Literature DB >> 2539700

Molecular cloning of a feline leukemia provirus integrated adjacent to the c-myc gene in a feline T-cell leukemia cell line and the unique structure of its long terminal repeat.

T Miura1, M Shibuya, H Tsujimoto, M Fukasawa, M Hayami.   

Abstract

This paper reports the molecular cloning of a rearranged c-myc region from the FT-1 cell line, which was derived from a spontaneous feline T-cell leukemia carrying the feline leukemia virus (FeLV). An abnormal c-myc EcoRI fragment of about 18 kilobases, detected by Southern blotting, was molecularly cloned from the DNA of the FT-1 cell line. The c-myc rearrangement in FT-1 was due to direct integration of the FeLV provirus genome immediately upstream of the c-myc gene in the opposite transcriptional orientation. Nucleotide sequencing showed that the LTR of this provirus had three copies of an enhancer-like sequence, unlike the sequences of FeLVs reported previously, which have only a single copy of this enhancer-like sequence.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539700     DOI: 10.1016/0042-6822(89)90172-4

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  13 in total

1.  Structure and function of the long terminal repeats of feline leukemia viruses derived from naturally occurring acute myeloid leukemias in cats.

Authors:  K Nishigaki; M Okuda; Y Endo; T Watari; H Tsujimoto; A Hasegawa
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

2.  Tumorigenic potential of a recombinant retrovirus containing sequences from Moloney murine leukemia virus and feline leukemia virus.

Authors:  C R Starkey; P A Lobelle-Rich; S W Granger; S Granger; B K Brightman; H Fan; L S Levy
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

3.  Structural diversity and nuclear protein binding sites in the long terminal repeats of feline leukemia virus.

Authors:  R Fulton; M Plumb; L Shield; J C Neil
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

4.  Substitution of feline leukemia virus long terminal repeat sequences into murine leukemia virus alters the pattern of insertional activation and identifies new common insertion sites.

Authors:  Chassidy Johnson; Patricia A Lobelle-Rich; Adriane Puetter; Laura S Levy
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  flvi-1, a common integration domain of feline leukemia virus in naturally occurring lymphomas of a particular type.

Authors:  K S Levesque; L Bonham; L S Levy
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

6.  Molecular cloning of feline leukemia provirus genomes integrated in the feline large granular lymphoma cells.

Authors:  Y Matsumoto; H Tsujimoto; M Fukasawa; Y Hirota; T Miura; M Hayami; R Goitsuka; K Ono; A Hasegawa
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

7.  Suppressor mutations within the core binding factor (CBF/AML1) binding site of a T-cell lymphomagenic retrovirus.

Authors:  M J Martiney; L S Levy; J Lenz
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

8.  Dominance of highly divergent feline leukemia virus A progeny variants in a cat with recurrent viremia and fatal lymphoma.

Authors:  A Katrin Helfer-Hungerbuehler; Valentino Cattori; Felicitas S Boretti; Pete Ossent; Paula Grest; Manfred Reinacher; Manfred Henrich; Eva Bauer; Kim Bauer-Pham; Eva Niederer; Edgar Holznagel; Hans Lutz; Regina Hofmann-Lehmann
Journal:  Retrovirology       Date:  2010-02-19       Impact factor: 4.602

9.  Feline leukemia virus detection by immunohistochemistry and polymerase chain reaction in formalin-fixed, paraffin-embedded tumor tissue from cats with lymphosarcoma.

Authors:  M L Jackson; D M Haines; S M Meric; V Misra
Journal:  Can J Vet Res       Date:  1993-10       Impact factor: 1.310

10.  Long terminal repeat enhancer core sequences in proviruses adjacent to c-myc in T-cell lymphomas induced by a murine retrovirus.

Authors:  H L Morrison; B Soni; J Lenz
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.